Related Experiment Video
Updated: May 9, 2026
Rapid and Efficient Zebrafish Genotyping Using PCR with High-resolution Melt Analysis
Published on: February 5, 2014
[Duplex genotyping of CYP2C19*2 and CYP2C19*3 by high-resolution melting curve analysis]
Chun-Ge Cao1, Hai-Yan Sun, Fang-Fang Zhou
1School of Life Science, Fudan University, Shanghai, China. michille2006@126.com
Insights
A new high-resolution melting curve (HRM) analysis method enables simultaneous, accurate genotyping of CYP2C19*2 and CYP2C19*3 gene variants. This aids in guiding clopidogrel dosage for patients, improving treatment efficacy.
Area of Science:
- Pharmacogenomics
- Molecular Diagnostics
Background:
- Clopidogrel is a vital anti-platelet medication for preventing arterial thrombosis.
- CYP2C19*2 and CYP2C19*3 genetic variants reduce clopidogrel's effectiveness by impairing its metabolic activation.
Purpose of the Study:
- To develop a simple, accurate, and simultaneous genotyping method for CYP2C19*2 and CYP2C19*3 variants.
- To enable personalized clopidogrel dosing strategies based on individual genetic profiles.
Main Methods:
- Design of two specific amplicons covering CYP2C19*2 and CYP2C19*3 variants.
- Utilizing high-resolution melting curve (HRM) analysis for simultaneous duplex genotyping in a closed-tube system.
- Incorporation of 5' primer tails to ensure distinct melting curves for each amplicon.
Main Results:
- Successful and sensitive duplex genotyping of 64 DNA samples using the developed HRM assay.
- Perfect concordance between HRM-based genotyping results and DNA sequencing validation.
- Demonstration of a simple, accurate, and simultaneous closed-tube method for CYP2C19*2 and CYP2C19*3 genotyping.
Conclusions:
- The developed HRM assay provides a reliable method for simultaneous CYP2C19*2 and CYP2C19*3 genotyping.
- This assay can be implemented in clinical laboratories to guide individualized clopidogrel dosage.
- Personalized medicine approaches using pharmacogenetic testing can optimize anti-platelet therapy outcomes.
Abstract:
Clopidogrel is a widely used anti-platelet agent for the prevention of arterial thrombosis. It has been suggested that clopidogrel may be less effective in inhibiting platelet aggregation among patients who are carriers of CYP2C19*2 and CYP2C19*3, two loss-of-function CYP2C19 alleles, which are associated with reduced conversion of clopidogrel to its active metabolite. The objective of this research was to develop a simple and accurate method for genotyping of CYP2C19*2 and CYP2C19*3 simultaneously in one closed-tube using high-resolution melting curve (HRM) analysis. Two amplicons bracketing CYP2C19*2 and CYP2C19*3 gene variants were designed, and AT- or GC-rich 5' tails were added to selected primers to ensure two different amplicons with non-overlapping melting curves. Sixty-four random DNA samples were all fast and sensitively genotyped by HRM analysis. This method was validated by DNA sequencingtechnique, and genotypes obtained using the HRM approach perfectly matched the genotypes obtained by DNA sequencing technique. Therefore, this HRM-based assay allows simple and accurate duplex genotyping of CYP2C19*2 and CYP2C19*3 simultaneously in one closed-tube. This method is expected to be applied in clinical laboratory to guide indi-vidual dosage design of clopidogrel.
